Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of subcutaneous versus intravenous frexalimab in adults with multiple sclerosis
2024-519304-28-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of frexalimab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Sanofi. Primary endpoints: Area under the curve over the interval Week 20 to Week 24 and Trough concentration at steady state. Planned start Apr 2026; status: authorised.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-519304-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519304-28-00.